Q1 Earnings Forecast for TENX Issued By Leerink Partnrs

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a research note issued to investors on Wednesday, March 26th. Leerink Partnrs analyst D. Risinger forecasts that the specialty pharmaceutical company will post earnings per share of ($1.06) for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($3.52) EPS, Q4 2025 earnings at ($4.73) EPS, FY2025 earnings at ($10.46) EPS, FY2026 earnings at ($5.76) EPS, FY2027 earnings at ($4.86) EPS, FY2028 earnings at ($3.08) EPS and FY2029 earnings at ($1.03) EPS.

A number of other research analysts have also recently issued reports on the stock. StockNews.com began coverage on shares of Tenax Therapeutics in a report on Saturday. They set a “sell” rating for the company. Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday, March 10th. Finally, William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Price Performance

TENX opened at $6.36 on Monday. The company’s 50 day simple moving average is $6.44 and its 200-day simple moving average is $5.48. The stock has a market capitalization of $25.25 million, a P/E ratio of -1.20 and a beta of 2.20. Tenax Therapeutics has a one year low of $2.77 and a one year high of $7.89.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.34.

Institutional Trading of Tenax Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Two Sigma Investments LP acquired a new position in Tenax Therapeutics in the 4th quarter valued at about $84,000. Millennium Management LLC bought a new position in shares of Tenax Therapeutics during the fourth quarter worth approximately $166,000. Janus Henderson Group PLC acquired a new stake in Tenax Therapeutics during the 4th quarter worth approximately $1,026,000. Geode Capital Management LLC boosted its stake in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 5,964 shares during the period. Finally, Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics in the 3rd quarter valued at $101,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.